Cited by 2,604Heart Failure Treatment and ManagementRenin-Angiotensin System StudiesHeart rate and cardiovascular health

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

McMurray, John JV, Östergren, Jan, Swedberg, Karl, Granger, Christopher B, Held, Peter, Michelson, Eric L, Olofsson, Bertil, Yusuf, Salim, Pfeffer, Marc A·2003·The Lancet

DOI 10.1016/s0140-6736(03)14283-3

Open this paper in CoChat — free account

Abstract

Background Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic measurements, neurohumoral activity, and left-ventricular remodelling when added to angiotensin-converting-enzyme (ACE) inhibitors in patients with chronic heart failure (CHF). We aimed to find out whether these drugs improve clinical outcome.Methods Between March, 1999, and November, 1999, we enrolled 2548 patients with New York Heart Association functional class II-IV CHF and left-ventricular ejection fraction 40% or lower, and who were being treated with ACE inhibitors. We randomly assigned patients candesartan (n=1276, target dose 32 mg once daily) or placebo (n=1272). At baseline, 55% of patients were also treated with beta blockers and 17% with spironolactone. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was done by intention to treat.Findings The median follow-up was 41 months. 483 (38%) patients in the candesartan group and 538 (42%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.85 [95% CI 0.75-0.96], p=0.011; covariate adjusted p=0.010). Candesartan reduced each of the components of the primary outcome significantly, as well as the total number of hospital admissions for CHF. The benefits of candesartan were similar in all predefined subgroups, including patients receiving baseline beta blocker treatment.Interpretation The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)14283-3

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure
Garg, R. (1995) · JAMA · doi:10.1001/jama.273.18.1450 · Cited by 1,993
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01683-7 · Cited by 1,909
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citation
Guidelines for the diagnosis and treatment of chronic heart failure
Remme, W. J. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,595
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M. A., Hall, A. S., Murray, G. D., Torp-Pedersen, C. T., Ball, S. G., Pogue, J. M., Moyé, L. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02212-1 · Cited by 1,585
Self-citation
The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis
Cleland, J. G. F. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00823-0 · Cited by 1,553
ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)
Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldman, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., Jessup, M. L., et al. (2001) · Circulation · doi:10.1161/hc4901.102568 · Cited by 1,440
Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure
Packer, M., O’Connor, C. M., Ghali, J. K., Pressler, M. L., Carson, P. E., Belkin, R. N., Miller, A. B., Neuberg, G. W., Frid, D. J., WERTHEIMER, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351504 · Cited by 1,194

Show all 38 references

Sorted by citations

Items 401–500 of 1,001

Tissue Advanced Glycation end Products are Associated with Diastolic Function and Aerobic Exercise Capacity in Diabetic Heart Failure Patients
Willemsen, S., Hartog, J. W. L., Hummel, Y. M., van Ruijven, M. H., van der Horst, I. C. C., van Veldhuisen, D. J., & Voors, A. A. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq168 · Cited by 77
Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice
Zhang, G., Ohmori, K., Nagai, Y., Fujisawa, Y., Nishiyama, A., Abe, Y., & Kimura, S. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.01.012 · Cited by 77
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program
Vazir, A., Claggett, B. L., Jhund, P. S., Castagno, D., Skali, H., Yusuf, S., Swedberg, K. B., Granger, C. B., McMurray, J. J. V., Pfeffer, M. A., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu401 · Cited by 77
Self-citation
Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
Preiss, D., Zetterstrand, S., McMurray, J. J. V., Östergren, J., Michelson, E. L., Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A., Gerstein, H. C., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1709 · Cited by 76
Self-citation
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure
Kim, M., Lee, J., Kim, E. J., Park, D.-G., Park, S., Park, J. J., Shin, M., Yoo, B., Youn, J., Lee, S. E., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0009 · Cited by 76
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Ambrosy, A. P., Duffy, C. I., McCague, K., Hernandez, A. F., Rocha, R. A., & Braunwald, E. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.01.004 · Cited by 76
Hypertension and Diabetes
Grossman, E., & Messerli, F. H. (2008) · KARGER eBooks · doi:10.1159/000115189 · Cited by 76
N-terminal Pro Brain Natriuretic Peptide-Guided Management in Patients with Heart Failure and Preserved Ejection Fraction: Findings from the Trial of Intensified Versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF)
Maeder, M. T., Rickenbacher, P. R., Rickli, H., Abbühl, H., Gutmann, M., Erné, P., Vuilliomenet, A., Peter, M., Pfisterer, M. E., Rocca, H. B., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft076 · Cited by 75
The renin-angiotensin system and insulin resistance
Liu, Z. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0007-5 · Cited by 76
How robust are clinical trials in heart failure?
Docherty, K. F., Campbell, R. T., Jhund, P. S., Petrie, M. C., & McMurray, J. J. V. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw427 · Cited by 75
Self-citation
Diabetes and Drug-Associated Hyperkalemia: Effect of Potassium Monitoring
Raebel, M. A., Ross, C. A., Xu, S., Roblin, D. W., Cheetham, C., Blanchette, C. M., Saylor, G., & Smith, D. H. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-009-1228-x · Cited by 75
Comparative Effectiveness of Different β-Adrenergic Antagonists on Mortality Among Adults With Heart Failure in Clinical Practice
Go, A. S., Yang, J., Gurwitz, J. H., Hsu, J., Lane, K., & Platt, R. G. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.506 · Cited by 73
Geographic Differences in Heart Failure Trials
Ferreira, J. P., Girerd, N., Rossignol, P., & Zannad, F. M. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.326 · Cited by 74
A review of heart failure management in the elderly population
Cheng, J. W. M., & Nayar, M. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.10.001 · Cited by 73
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors Task Force Members, Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., et al. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/ehl261 · Cited by 76
Self-citation
Optimal Pharmacologic and Non-pharmacologic Management of Cardiac Transplant Candidates: Approaches to Be Considered Prior to Transplant Evaluation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates—2006
Jessup, M. L., Banner, N. R., Brozena, S. C., Campana, C., Costard‐Jäckle, A., Dengler, T. J., Hunt, S. A., Metra, M., Rahmel, A. O., Renlund, D. G., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.06.007 · Cited by 73
Which Inhibitor of the Renin–Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction?
McMurray, J. J. V., Pfeffer, M. A., Swedberg, K. B., & Dzau, V. J. (2004) · Circulation · doi:10.1161/01.cir.0000147274.83071.68 · Cited by 74
Self-citation
Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation
Perego, C., Sbolli, M., Specchia, C., Fiuzat, M., McCaw, Z. R., Metra, M., Oriecuia, C., Peveri, G., Wei, L., O’Connor, C. M., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.07.005 · Cited by 72
Renin–Angiotensin System Blocking Drugs
Robles, N. R., Cerezo, I., & Hernández‐Gallego, R. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501018 · Cited by 74
The Role of Angiotensin Receptor Blockers in Patients with Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
Beavers, C. J., Dunn, S. P., & Macaulay, T. E. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p630 · Cited by 72
Impact of Systolic Blood Pressure on the Safety and Tolerability of Initiating and Up-Titrating Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction: Insights from the TITRATION Study
Senni, M., McMurray, J. J. V., Wachter, R., McIntyre, H. F., Anand, I. S., Duino, V., Sarkar, A., Shi, V. C., & Charney, A. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1054 · Cited by 72
Self-citation
Diabetic cardiomyopathy
Lorenzo-Almorós, A., Cepeda-Rodrigo, J. M., & Lorenzo, Ó. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.10.012 · Cited by 74
Guideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Patel, J., Rassekh, N., Fonarow, G. C., DEEDWANIA, P. C., Sheikh, F. H., Ahmed, A., & Lam, P. H. (2023) · Drugs · doi:10.1007/s40265-023-01887-4 · Cited by 74
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
Janse, R. J., Fu, E. L., Dahlström, U., Benson, L., Lindholm, B., van Diepen, M., Dekker, F. W., Lund, L. H., Carrero, J. J., & Savarese, G. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2620 · Cited by 71
Implementation of a pharmacist-managed heart failure medication titration clinic
Martinez, A., Saef, J., Paszczuk, A., & Bhatt-Chugani, H. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120267 · Cited by 70
Systems Pharmacology Dissection of the Integrated Treatment for Cardiovascular and Gastrointestinal Disorders by Traditional Chinese Medicine
Zhang, W., Qin, T., Guo, Z., Fu, Y., Chen, X., Shar, P. A., Shahen, M., Zhu, J., Xue, J., Bai, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep32400 · Cited by 70
Cheyne–Stokes respiration with central sleep apnoea in chronic heart failure: Proposals for a diagnostic and therapeutic strategy
Pépin, J., Chouri-Pontarollo, N., Tamisier, R., & Levy, P. A. (2005) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2005.10.003 · Cited by 70
The Top 10 Hot Topics in Aging
Morley, J. E. (2004) · The Journals of Gerontology Series A · doi:10.1093/gerona/59.1.m24 · Cited by 70
Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy
Malgie, J., Clephas, P. R. D., Rocca, H. B., de Boer, R. A., & Brugts, J. J. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10325-2 · Cited by 76
The Relationship between Left Ventricular Ejection Fraction and Mortality in Patients with Acute Heart Failure: Insights from the ASCEND-HF Trial
Toma, M., Ezekowitz, J. A., Bakal, J. A., O’Connor, C. M., Hernandez, A. F., Sardar, M. R., Zolty, R., Massie, B. M., Swedberg, K. B., Armstrong, P. W., et al. (2013) · European Journal of Heart Failure · doi:10.1002/ejhf.19 · Cited by 69
Self-citation
Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure
Okazaki, Y., Zheng, C., Li, M., & Sugimachi, M. (2009) · The Journal of Physiological Sciences · doi:10.1007/s12576-009-0071-5 · Cited by 69
Gender Differences in Clinical Characteristics, Treatment and Long-Term Outcome in Patients With Stage C/D Heart Failure in Japan
Sakata, Y., Miyata, S., Nochioka, K., Miura, M., Takada, T., Tadaki, S., Takahashi, J. A., & Shimokawa, H. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-1009 · Cited by 69
Analysis of Factors Causing Hyperkalemia
Takaichi, K., Takemoto, F., Ubara, Y., & Mori, Y. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6415 · Cited by 69
A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction
Gluckman, T. J., Baranowski, B. J., Ashen, M. D., Henrikson, C. A., McAllister, M. W., Braunstein, J. B., & Blumenthal, R. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1490 · Cited by 69
Association of Candesartan vs Losartan With All-Cause Mortality in Patients With Heart Failure
Eklind-Cervenka, M. (2011) · JAMA · doi:10.1001/jama.2010.1949 · Cited by 68
International Variations in the Treatment and Co-Morbidity of Left Ventricular Systolic Dysfunction: Data from the EuroHeart Failure Survey
Lainščak, M., Cleland, J. G. F., Lenzen, M. J., Folláth, F., Michel Komajda, N., & Swedberg, K. B. (2006) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2006.07.007 · Cited by 68
Self-citation
Methods used for the assessment of LV systolic function: common currency or tower of Babel?
Marwick, T. H. (2013) · Heart · doi:10.1136/heartjnl-2012-303433 · Cited by 68
Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy
Schmidt, S., Hürlimann, D., Starck, C. T., Hindricks, G., Lüscher, T. F., Ruschitzka, F. T., & Steffel, J. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht514 · Cited by 68
Understanding Heart Failure
Mazurek, J. A., & Jessup, M. L. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.07.001 · Cited by 75
Angiotensin II Type 1 Receptor Blocker Attenuates Myocardial Remodeling and Preserves Diastolic Function in Diabatic Heart
Tsutsui, H., Matsushima, S., Kinugawa, S., Ide, T., Inoue, N., Ohta, Y., Yokota, T., Hamaguchi, S., & Sunagawa, K. (2007) · Hypertension Research · doi:10.1291/hypres.30.439 · Cited by 68
Devices in the management of advanced, chronic heart failure
Abraham, W. T., & Smith, S. A. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.178 · Cited by 68
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients
Chan, K. E., Ikizler, T. A., Gamboa, J. L., Yu, C., Hakim, R. M., & Brown, N. J. (2011) · Kidney International · doi:10.1038/ki.2011.228 · Cited by 67
Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer
Cheuk, D. K., Sieswerda, E., van Dalen, E. C., Postma, A., & Kremer, L. C. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008011.pub3 · Cited by 67
Prognostic Impact of NT-proBNP and Renal Function in Comparison to Contemporary Multi-Marker Risk Scores in Heart Failure Patients
Pfister, R., Diedrichs, H., Schiedermair, A., Rosenkranz, S., Hellmich, M., Erdmann, E., & Schneider, C. A. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.01.009 · Cited by 67
Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial
Sakata, Y., Shiba, N., TAKAHASHI, J. C., Miyata, S., Nochioka, K., Miura, M., Takada, T., Saga, C., Shinozaki, T., Sugi, M., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu504 · Cited by 67
Treatment of chronic kidney disease in older populations
Kishi, S., Kadoya, H., & Kashihara, N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00854-w · Cited by 69
Practical Applications of Intravenous Diuretic Therapy in Decompensated Heart Failure
Cleland, J. G. F., Coletta, A. P., & Witte, K. K. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.09.014 · Cited by 66
Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction
Tromp, J., Ouwerkerk, W., Teng, T. K., Cleland, J. G. F., Bamadhaj, S., Angermann, C. E., Dahlström, U., Tay, W. T., Dickstein, K., Ertl, G., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac103 · Cited by 66
Impact of the renin–angiotensin system on cardiac energy metabolism in heart failure
Mori, J., Zhang, L., Oudit, G. Y., & Lopaschuk, G. D. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.07.010 · Cited by 65
Improving Survival Rates of Patients With Idiopathic Dilated Cardiomyopathy in Tuscany Over 3 Decades
Castelli, G., Fornaro, A., Ciaccheri, M., Dolara, A., Troiani, V., Tomberli, B., Olivotto, I., & Gensini, G. F. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000120 · Cited by 65
Molecular Imaging for Efficacy of Pharmacologic Intervention in Myocardial Remodeling
van den Borne, S. W. M., Isobe, S., Zandbergen, H. R., Li, P., Petrov, A. D., Wong, N. D., Fujimoto, S., Fujimoto, A., Løvhaug, D., Smits, J. F. M., et al. (2009) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2008.11.011 · Cited by 65
Heart Failure and Nephropathy
Gilbert, R. E., Connelly, K. A., Kelly, D. J., Pollock, C. A., & Krum, H. (2005) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00540705 · Cited by 66
Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction
Desai, A. S., Claggett, B. L., Pfeffer, M. A., Bello, N. A., Finn, P. V., Granger, C. B., McMurray, J. J. V., Pocock, S., Swedberg, K. B., Yusuf, S., et al. (2014) · Circulation Heart Failure · doi:10.1161/circheartfailure.114.001567 · Cited by 65
Self-citation
Hypertension and the Cardiometabolic Syndrome
Manrique, C. M., Lastra, G., Whaley‐Connell, A. T., & Sowers, J. R. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04617.x · Cited by 65
The Pleiotropic Effects of Angiotensin Receptor Blockers
Chrysant, S. G., & Chrysant, G. S. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.05264.x · Cited by 65
Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure
Tomaschitz, A., Pilz, S., Ritz, E., Morganti, A., Grammer, T., Amrein, K., Boehm, B. O., & Marz, W. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr150 · Cited by 64
Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline
Mant, J., Al‐Mohammad, A., Swain, S., Laramée, P., & for the Guideline Development Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-4-201108160-00009 · Cited by 65
Structural basis for telmisartan-mediated partial activation of PPAR gamma
Amano, Y., Yamaguchi, T., Ohno, K., Niimi, T., Orita, M., Sakashita, H., & Takeuchi, M. (2012) · Hypertension Research · doi:10.1038/hr.2012.17 · Cited by 65
Targeting the ACE2–Ang-(1–7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure
Iwata, M., Cowling, R. T., Yeo, S. J., & Greenberg, B. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.12.003 · Cited by 64
Interaction Between Baseline and Early Worsening of Renal Function and Efficacy of Renin–Angiotensin–Aldosterone System Blockade in Patients with Heart Failure: Insights from the Val-HeFT Study
Lesogor, A., Cohn, J. N., Latini, R., Tognoni, G., Krum, H., Massie, B. M., Zalewski, A. A., Kandra, A., Hua, T. A., & Gimpelewicz, C. R. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft089 · Cited by 64
The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End Point
Messerli, F. H. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.036 · Cited by 64
Clinical Relevance of Local Renin Angiotensin Systems
Campbell, D. J. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00113 · Cited by 66
Antagonist of the Type-1 ANG II receptor prevents against LPS-induced septic shock in rats
Hagiwara, S., Iwasaka, H., Hidaka, S., Hasegawa, A., Koga, H., & Noguchi, T. (2009) · Intensive Care Medicine · doi:10.1007/s00134-009-1545-x · Cited by 64
Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly
Turgut, F. H., Balogun, R. A., & Abdel‐Rahman, E. M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08611209 · Cited by 65
Angiotensin Receptor Blockers: Current Status and Future Prospects
Ram, C. V. S. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.02.038 · Cited by 64
Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure
Khan, M. S., Fonarow, G. C., Ahmed, A. M., Greene, S. J., Vaduganathan, M., Khan, H., Marti, C. N., Gheorghiade, M., & Butler, J. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.003956 · Cited by 64
American Heart Association Scientific Sessions
Winkelmann, B. R. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.435 · Cited by 64
The role of Pyruvate Dehydrogenase Complex in cardiovascular diseases
Sun, W., Liu, Q., Leng, J., Zheng, Y., & Li, J. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.11.030 · Cited by 64
Comparison of Three-Year Outcomes After Primary Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fraction <40% Versus ≥40% (from the HORIZONS-AMI Trial)
Daneault, B., Généreux, P., Kirtane, A. J., Witzenbichler, B., Guagliumi, G., Paradis, J., Fahy, M. P., Mehran, R., & Stone, G. W. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.040 · Cited by 63
Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure
Bourge, R. C., Fleg, J. L., Fonarow, G. C., Cleland, J. G. F., McMurray, J. J. V., van Veldhuisen, D. J., Gheorghiade, M., Patel, K., Aban, I., Allman, R. M., et al. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.02.001 · Cited by 63
Self-citation
Contribution of Cardiac and Extra-Cardiac Disease Burden to Risk of Cardiovascular Outcomes Varies by Ejection Fraction in Heart Failure
Wolsk, E., Claggett, B. L., Køber, L., Pocock, S., Yusuf, S., Swedberg, K. B., McMurray, J. J. V., Granger, C. B., Pfeffer, M. A., & Solomon, S. D. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1073 · Cited by 63
Self-citation
Validity of claims‐based definitions of left ventricular systolic dysfunction in Medicare patients
Li, Q., Glynn, R. J., Dreyer, N. A., Liu, J., Mogun, H., & Setoguchi, S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2146 · Cited by 62
Prevalence and Prognostic Impact of Bundle Branch Block in Patients with Heart Failure: Evidence from the CHARM Programme
Hawkins, N. M., Wang, D., McMurray, J. J. V., Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Yusuf, S., Pocock, S., Östergren, J., Michelson, E. L., et al. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2006.11.006 · Cited by 62
Self-citation
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
Kjeldsen, S. E., Stålhammar, J., Hasvold, P., Bodegård, J., Olsson, U., & Russell, D. (2009) · Journal of Human Hypertension · doi:10.1038/jhh.2009.77 · Cited by 62
Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model
Rogers, J. K., Yaroshinsky, A., Pocock, S., Stokar, D., & Pogoda, J. M. (2016) · Statistics in Medicine · doi:10.1002/sim.6853 · Cited by 62
2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter
Heidenreich, P. A., Solis, P., Estes, N. A. M., Fonarow, G. C., Jurgens, C. Y., Marine, J. E., McManus, D. D., & McNamara, R. L. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000018 · Cited by 62
The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future
Orsborne, C., Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134045 · Cited by 68
Antihypertensive therapy and new onset diabetes
Messerli, F. H., Grossman, E., & Leonetti, G. (2004) · Journal of Hypertension · doi:10.1097/00004872-200410000-00001 · Cited by 62
Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.
Munger, M. A. (2011) · PubMed Central · Cited by 61
Understanding acute heart failure: pathophysiology and diagnosis
Arrigo, M., Parissis, J., Akiyama, E., & Mebazaa, A. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw044 · Cited by 71
Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival
Akita, K., Kohno, T., Kohsaka, S., Shiraishi, Y., Nagatomo, Y., Izumi, Y., Goda, A., Mizuno, A., Sawano, M., Inohara, T., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.070 · Cited by 61
Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway
Pellieux, C., Aasum, E., Larsen, T. S., Montessuit, C., Papageorgiou, I., Pedrazzini, T., & Lerch, R. A. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.004 · Cited by 61
Efficacy and Tolerability of Fimasartan, a New Angiotensin Receptor Blocker, Compared With Losartan (50/100 mg): A 12-Week, Phase III, Multicenter, Prospective, Randomized, Double-Blind, Parallel-Group, Dose Escalation Clinical Trial With an Optional 12-Week Extension Phase in Adult Korean Patients With Mild-to-Moderate Hypertension
Lee, S. E., Kim, Y.-J., Lee, H., Yang, H., Park, C. G., Kim, J., Kim, S.-K., Rhee, M., & Oh, B. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.01.024 · Cited by 60
Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons
Qaseem, A., Fihn, S. D., Dallas, P., Williams, S., Owens, D. K., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00011 · Cited by 60
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-γ
Pershadsingh, H. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.08.006 · Cited by 62
Guideline-Directed Medical Therapy for Heart Failure does not Exist: A Non-Judgmental Framework for Describing the Level of Adherence to Evidence-Based Drug Treatments for Patients with a Reduced Ejection Fraction
Packer, M., & Metra, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1857 · Cited by 59
Comparison of Characteristics and Outcomes of Patients With Heart Failure Preserved Ejection Fraction Versus Reduced Left Ventricular Ejection Fraction in an Urban Cohort
Quiroz, R., Doros, G. D., Shaw, P., Liang, C., Gauthier, D. F., & Sam, F. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.11.014 · Cited by 59
Hyperkalemia in patients with heart failure: Incidence, prevalence, and management
Desai, A. S. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0037-1 · Cited by 59
Angioedema induced by angiotensin-converting enzyme inhibitors
Campo, P., Fernández, T. D., Cantó, G., & Mayorga, C. (2013) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e328362b835 · Cited by 59
Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ontarget--a call for more circumspection
Onuigbo, M. A. C. (2008) · QJM · doi:10.1093/qjmed/hcn142 · Cited by 59
Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction
de Denus, S., Tardif, J., White, M., Bourassa, M. G., Racine, N., Lévesque, S., & Ducharme, A. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.05.030 · Cited by 59
Changes in endothelium‐derived hyperpolarizing factor in hypertension and ageing: response to chronic treatment with renin–angiotensin system inhibitors
Gotō, K., Fujii, K., Kansui, Y., & Iida, M. (2004) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2004.04054.x · Cited by 59
Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
Bahtiyar, G., Gutterman, D. D., & Lebovitz, H. E. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0809-4 · Cited by 60
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L. L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter
Heidenreich, P. A., Solis, P., Estes, N. A. M., Fonarow, G. C., Jurgens, C. Y., Marine, J. E., McManus, D. D., & McNamara, R. L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.521 · Cited by 58
Improvement in the Management of Chronic Heart Failure Since the Publication of the Updated Guidelines of the European Society of Cardiology
de Groote, P., Isnard, R., Clerson, P., Jondeau, G., Galinier, M., Assyag, P., Demil, N., Ducardonnet, A., Thébaut, J.-F., & Michel Komajda, N. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn005 · Cited by 58
Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds
Volpe, M., Mancia, G., & Trimarco, B. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000194114.12228.16 · Cited by 58
Bundesärztekammer Kassenärztliche Bundesvereinigung Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
VersorgungsLeitlinie, N. (2011) · Cited by 58
β-Arrestin mediates the Frank–Starling mechanism of cardiac contractility
Abraham, D., Davis, R. T., Warren, C. M., Mao, L., Wolska, B. M., Solaro, R. J., & Rockman, H. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609308113 · Cited by 57
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure
Ferreira, J. P., Zannad, F. M., Butler, J., Filippatos, G. S., Pocock, S., Brueckmann, M., Steubl, D., Schueler, E., Anker, S. D., & Packer, M. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2924 · Cited by 57

Authors: McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A.
Affiliations: University of Glasgow (GB)
Karolinska University Hospital (SE)
Sahlgrenska University Hospital (SE)
Duke Medical Center (US)
AstraZeneca (Sweden) (SE)
AstraZeneca (United States) (US)
Hamilton Health Sciences (CA)
Brigham and Women's Hospital (US)
Corresponding author: McMurray, John JV
ORCID: McMurray, John JV
Östergren, Jan
Swedberg, Karl
Granger, Christopher B
Yusuf, Salim
Pfeffer, Marc A
Venue: The Lancet
Publisher: Elsevier BV
Published: 2003-09
Volume: 362
Issue: 9386
Pages: 767-771
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(03)14283-3
OpenAlex: W2098780362
Cited by: 2,604
References: 38
Citations by year: 2026: 8 · 2025: 15 · 2024: 46 · 2023: 52 · 2022: 58 · 2021: 60 · 2020: 98 · 2019: 82 · 2018: 66 · 2017: 103 · 2016: 108 · 2015: 118 · 2014: 122 · 2013: 126 · 2012: 153
FWCI: 122.65
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords: candesartan, chronic heart failure, reduced left ventricular ejection fraction, angiotensin receptor blockers, ACE inhibitors, combination therapy, cardiovascular mortality, beta-blockers, spironolactone
MeSH terms: Adolescent, Adult, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Cardiac Output, Low, Cardiovascular Diseases, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Placebos, Tetrazoles, Comorbidity, Treatment Outcome, Ventricular Dysfunction, Left, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks